Fever

Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities

Retrieved on: 
Mittwoch, März 6, 2024

“People with HIV and comorbid conditions or pre-existing treatment resistance can often face complex and evolving treatment needs.

Key Points: 
  • “People with HIV and comorbid conditions or pre-existing treatment resistance can often face complex and evolving treatment needs.
  • The ALLIANCE trial is the first randomized clinical trial of TAF- vs TDF-based regimens in treatment naïve adults with HIV /HBV coinfection.
  • Additionally, ALLIANCE participants treated with Biktarvy exhibited numerically higher levels of HBV viral suppression and seroconversion.
  • The primary outcome measure is viral suppression rates at Week 24, defined as HIV-1 RNA ˂50 copies/mL.

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

Retrieved on: 
Montag, Februar 19, 2024

In addition, TAGRISSO plus chemotherapy was recently approved in the US based on the FLAURA2 Phase III trial.

Key Points: 
  • In addition, TAGRISSO plus chemotherapy was recently approved in the US based on the FLAURA2 Phase III trial.
  • Interstitial lung disease (ILD)/pneumonitis occurred in 4% of the 1813 TAGRISSO-treated patients; 0.4% of cases were fatal.
  • TAGRISSO is the only targeted therapy to improve patient outcomes in both early-stage disease in the ADAURA Phase III trial and late-stage disease in the FLAURA Phase III trial and FLAURA2 Phase III trial .
  • AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

Taro Expands Branded Over-the-Counter Portfolio in U.S. with the Launch of FeverAll® Liquid Oral Acetaminophen for Children Ages 2-11

Retrieved on: 
Mittwoch, März 6, 2024

HAWTHORNE, N.Y., March 6, 2024 /PRNewswire-PRWeb/ -- Taro Pharmaceuticals U.S.A., Inc., a subsidiary of Taro Pharmaceutical Industries Ltd. (NYSE: TARO), today announced the expansion of its growing FeverAll® children's fever brand with a new liquid oral acetaminophen suspension format. New FeverAll® Children's Liquid Oral Acetaminophen, available in cherry and grape flavors, complements the brand's current offerings, which include three dosing levels of the doctor-recommended FeverAll® Acetaminophen Suppositories. The new liquid, which comes with a child-designed 15ml dosing cup, offers parents an additional option for the temporary relief of pain and fever in children aged two to 11, while the popular 80 mg suppository can be utilized in children as young as six months' of age.

Key Points: 
  • New oral liquid format expands the FeverAll® family of products, giving parents more options from the doctor-recommended suppository brand.
  • HAWTHORNE, N.Y., March 6, 2024 /PRNewswire-PRWeb/ -- Taro Pharmaceuticals U.S.A., Inc., a subsidiary of Taro Pharmaceutical Industries Ltd. (NYSE: TARO), today announced the expansion of its growing FeverAll® children's fever brand with a new liquid oral acetaminophen suspension format.
  • New FeverAll® Children's Liquid Oral Acetaminophen, available in cherry and grape flavors, complements the brand's current offerings, which include three dosing levels of the doctor-recommended FeverAll® Acetaminophen Suppositories.
  • FeverAll® Liquid Oral Acetaminophen will launch on Amazon and will expand to other retailers in time for the cold and flu season.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS

Retrieved on: 
Dienstag, Februar 27, 2024

NASHVILLE, Tenn., Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024.

Key Points: 
  • NASHVILLE, Tenn., Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024.
  • A conference call will be held on March 5 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.

Public advisory - APO-Mometasone nasal spray: Two lots recalled due to possible risk of infection

Retrieved on: 
Montag, Februar 19, 2024

Apotex Inc. is recalling two lots of APO-Mometasone nasal spray due to possible bacterial contamination with Burkholderia cepacia complex (Bcc).

Key Points: 
  • Apotex Inc. is recalling two lots of APO-Mometasone nasal spray due to possible bacterial contamination with Burkholderia cepacia complex (Bcc).
  • APO-Mometasone nasal spray is a prescription drug used to treat seasonal and year-round nasal allergy symptoms (such as itchy, stuffy or runny nose and sneezing) in children 3-11 years old.
  • It is also used to treat sinusitis (sinus inflammation) in adults and children 12 years of age and older, and nasal polyps in adults.
  • The effects of Bcc vary widely, ranging from no symptoms at all to serious infections.

FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

Retrieved on: 
Freitag, Februar 16, 2024

"Unresectable or metastatic melanoma is an aggressive form of cancer that can be fatal," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research (CBER).

Key Points: 
  • "Unresectable or metastatic melanoma is an aggressive form of cancer that can be fatal," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research (CBER).
  • Melanoma can spread to other parts of the body if not detected and treated early, resulting in metastatic disease.
  • Treatment for unresectable or metastatic melanoma may include immunotherapy using PD-1 inhibitors, which are antibodies targeting certain proteins in the body to help the immune system fight off cancer cells.
  • Those patients whose melanoma has progressed with these therapies have a high unmet medical need.

FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure

Retrieved on: 
Freitag, Februar 16, 2024

Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.

Key Points: 
  • Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.
  • "While it will not eliminate food allergies or allow patients to consume food allergens freely, its repeated use will help reduce the health impact if accidental exposure occurs."
  • Current treatment requires strict avoidance of the food(s) the patient is allergic to, and prompt administration of epinephrine to treat anaphylaxis should accidental exposures occur.
  • Xolair is the first FDA-approved medication to reduce allergic reactions to more than one type of food after accidental exposure.

Herbal medicinal product: Polypodii rhizomaArray, C: ongoing call for scientific data

Retrieved on: 
Freitag, Februar 16, 2024

Overview

Key Points: 
  • Overview
    This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of polypody rhizome.
  • The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing polypody rhizome.
  • Herbal medicines containing this polypody rhizome preparation are usually available as herbal tea to be drunk or in solid forms to be taken by mouth.
  • Polypody rhizome preparations may also be found in combination with other herbal substances in some herbal medicines.

How worried should I be about cryptosporidiosis? Am I safe at the pool?

Retrieved on: 
Donnerstag, Februar 15, 2024

More than 700 cases of this gastrointestinal disease were reported in Queensland in January, which is 13 times more than in January last year.

Key Points: 
  • More than 700 cases of this gastrointestinal disease were reported in Queensland in January, which is 13 times more than in January last year.
  • Read more:
    What lies beneath: the bugs lurking in your swimming pool

What causes cryptosporidiosis, and who is affected?

  • Cryptosporidum hominis only affects humans and is the major cause of recent outbreaks in Australia, while Cryptosporidium parvum can also affect animals.
  • The infection is spread by spores called oocysts in the stools of humans and animals.
  • Cryptosporidiosis is more prevalent in young children, particularly those under five, but the disease can affect people of any age.

So how do we catch it?

  • The largest recorded outbreak occurred in Milwaukee in 1993 where 403,000 people were believed to have been infected.
  • As few as ten oocysts can cause infection, making it possible for contaminated drinking water to affect a very large number of people.
  • Oocysts have been found in foods such as fresh vegetables and seafood but these are not common sources of infection in Australia.

What about chlorine?

  • Young children and in particular children in nappies are known to increase the potential for disease transmission in recreational water.
  • Proper nappy changing, frequent bathroom breaks and showering before swimming to remove faecal residue are helpful ways to reduce the risk.

Some sensible precautions


Other measures you can take to reduce yours and others’ risk of cryptosporidiosis include:
avoid swimming in natural waters such as rivers and creeks during and for at least three days after heavy rain
avoid swimming in beaches for at least one day after heavy rain
avoid drinking untreated water such as water from rivers or springs. If you need to drink untreated water, boiling it first will kill the Cryptosporidium
avoid swallowing water when swimming if you can
if you’ve had diarrhoea, avoid swimming for at least two weeks after it has resolved
avoid sharing towels or linen for at least two weeks after diarrhoea has resolved
avoid sharing, touching or preparing food that other people may eat for at least 48 hours after diarrhoea has resolved
wash your hands with soap and water after going to the bathroom or before preparing food (Cryptosporidium is not killed by alcohol gels and sanitisers).
Not all cases of diarrhoea are due to cryptosporidiosis. There are many other causes of infectious gastroenteritis and because the vast majority of the time recovery is uneventful you don’t need to see a doctor unless very unwell. If you do suspect you may have cryptosporidiosis you can ask your doctor to refer you for a stool test.
Vincent Ho does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

InventHelp Inventors Develop New Fever Pops for Children (AJD-203)

Retrieved on: 
Mittwoch, Februar 14, 2024

Our flavorful design would help reduce fever and pain while also providing added hydration."

Key Points: 
  • Our flavorful design would help reduce fever and pain while also providing added hydration."
  • The patent-pending invention provides a new way to administer ibuprofen or acetaminophen to children.
  • The invention features a unique design that is easy to consume so it is ideal for parents with young children, hospitals, etc.
  • 22-AJD-203, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.